#Warm Autoimmune Hemolytic Anemia Treatment Market

[bommagoni]

Warm Autoimmune Hemolytic Anemia Treatment Market Analysis

[stocklivemarket]

Here's what we can say about RIGL stock. A biotechnology business called Rigel Pharmaceuticals, Inc. finds and creates small molecule medications to treat cancer, uncommon immunological illnesses, and hematologic disorders. The business provides adults with chronic immune neutropenia Tavalisse, an oral splenic inhibitor of tyrosine kinase. Additionally, it produces the drug Fostamatinib, which is currently undergoing phase III clinical trials for the treatment of COVID-19, warm autoimmune hemolytic anemia, and COVID-19 patients who are hospitalized. The company is also working on R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor, which has successfully completed a phase I clinical trial for autoimmune and inflammatory diseases. As well as R289, a verbal interleukin understanding of the mechanism kinase 1/4 inhibitor, which is in phase I randomized study for autoimmune, inflammatory, and hematology-oncology diseases. Who Owns RIGL? Institutional investors own 73.88% of Rigel Pharmaceuticals (NASDAQ: RIGL), while insiders own 15.05% and individual investors own 11.07%. The largest individual shareholder of RIGL stock is Bvf Partners L P, which holds 16.66M shares, or 9.64% of the firm. Shares of Rigel Pharmaceuticals owned by Bvf Partners L P are presently valued at $13.89M. About RIGL It has research and license contracts with AstraZeneca AB for the development and marketing of R256, an inhaled JAK inhibitor, with BerGenBio AS for the development and marketing of AXL inhibitors in oncology, with Daiichi Sankyo for the development of murine double minute 2 inhibition for solid and cytological malignancies, and with Kissei Pharmaceutical Co., Ltd. for the licensing and supply of Fostamatinib. Additionally, the business and Eli Lilly and Company have a license agreement and a strategic partnership to co-develop and market R552 for a variety of indications, including inflammatory and autoimmune illnesses and other non-CNS disease development candidates. South San Francisco, California serves as the corporate headquarters for Rigel Pharmaceuticals, Inc. What Are The Consensus Ratings And Price Objective For Rigel Pharmaceuticals? The consensus recommendation for RIGL stock, based on the present 4 hold ratings and 3 buy ratings for RIGL stock, is Hold according to the ratings that 7 analysts have issued over the past year. With a high price goal of $15.00 and a low cost target of $1.00, Rigel Pharmaceuticals' average 12 month price forecast is $3.96. NASDAQ ticker RIGL stock is used to identify Rigel Pharmaceuticals when trading on the NASDAQ. Stock quotations for Rigel Pharmaceuticals may alternatively be shown as NASDAQ: RIGL. The current share price for Rigel Pharmaceuticals is $0.83 (NASDAQ: RIGL) (as of Dec 2, 2022). (NYSE MKT: RIGL) There are now 172,836,336 shares of Rigel Pharmaceuticals outstanding. The market capitalization of Rigel Pharmaceuticals is $144.15M, with the stock now selling at $0.83 per share. On November 29, 2000, RIGL stock went public at a price of $63.99. Your return over the past 22 years if you had purchased RIGL stock at $63.99 would have been -98.7%, for just an annualized return of -17.9%. Competitors Of RIGL Verastem (VSTM), Spectrum Pharmaceuticals (SPPI), Merrimack Pharmaceuticals (MACK), Fortress Biotech (FBIO), Bolt Biotherapeutics (BOLT), Infinity Pharmaceuticals (INFI), Clovis Oncology (CLVS), Molecular Templates (MTEM), XOMA (XOMA), and Lexicon Pharmaceuticals are some of Rigel Pharmaceuticals' primary rivals (LXRX). Each of these businesses belongs to the "biotechnology" sector. Analysts favor other medical firms more than Rigel Pharmaceuticals. While the typical consensus recommendation for medical firms is Buy, Rigel Pharmaceuticals' rating is Hold. Verastem And Rigel Pharmaceuticals Verastem is outperformed by Rigel Pharmaceuticals in terms of earnings and revenue. Rigel Pharmaceuticals is currently the more cost-effective of the two stocks as it is selling at a cheaper cost ratio than Verastem.

With a beta of 0.63, Verastem's share price is predicted to be 37% less volatile than that of the S&P 500. When compared to the S&P 500, Rigel Pharmaceuticals does have a beta of 1.25, indicating that its RIGL stock price is 25% more volatile. When compared by MarketBeat users, Verastem received 150 more exceed votes than Rigel Pharmaceuticals. However, just 67.24% of individuals chose to vote for Verastem to outperform, compared to 69.61% who chose Rigel Pharmaceuticals. Institutional investors hold 58.6% of the shares of Verastem. Institutional investors now hold 80.9% of the shares of Rigel Pharmaceuticals. Insiders are the owners of 2.9% of the Verastem stock. Insiders own 6.4% of the shares of Rigel Pharmaceuticals, in contrast. A company's solid organizational ownership is a sign that hedge funds, big money managers, and endowments think it's prepared for long-term success. With a current consensus price objective of $5.00, Verastem might rise by 1,041.03%. With a $3.96 consensus price objective, Rigel Pharmaceuticals may rise by 374.91% from current levels. Analysts clearly perceive Verastem as being more favorable as Rigel Pharmaceuticals, given its higher consensus rating and more potential upside. What Date Will Rigel Pharmaceuticals Report Earnings? However, based on the report dates from the previous year, Rigel Pharmaceuticals estimates that its next earnings day will be on Tuesday, March 7, 2023. Rigel Pharmaceuticals (NASDAQ:RIGL) topped the analysts' consensus expectation of ($0.13) by $0.02 with its ($0.11) earnings per share (EPS) for the prior quarter. The reported yearly revenue for Rigel Pharmaceuticals (NASDAQ:RIGL) is $149.24 million. The reported net income for Rigel Pharmaceuticals (NASDAQ:RIGL) is -$17.91 million. Over the previous four quarters, RIGL's earnings per share were negative $0.48. Most Recent Analyst Recommendations From RIGL On December 2, 2022, Yigal Nochomovitz, a Citigroup bottom 6% analyst, increases RIGL to a solid investment rating. On November 4, 2022, Gary Nachman, a bottom 13% economist with BMO Capital, lowers their price objective for RIGL from $4 to $3 while maintaining a Buy recommendation. On August 18, 2022, Joseph Pantginis, rated bottom 10% analyst with HC Wainwright & Co., keeps RIGL with the a buy rating and increases their price objective from $7.00 to $15.00. On August 17, 2022, Do Kim, a high 33% analysts from Piper Sandler, retains RIGL with a hold recommendation and increases their price objective for the RIGL stock from $1.00 to $2.00. Financial Summary For RIGL Financial due diligence studies that RIGL passed show that it has a 70748000 cash burn. It has at least a year's worth of coverage in the form of cash and short-term investments. On the RIGL cash balance, short-term assets outnumber long-term liabilities. On the RIGL accounting records, short-term assets exceed short-term liabilities. Financial Due Diligence Tests that Fail: In the previous year, RIGL's profit margin decreased from -9.9% to -92.4%. The RIGL ratio of debt to equity is negative at -6.83. The total debt of RIGL is still negative. RIGL has $81.64M in short-term investments and cash. This is insufficient to fund its $70.75M yearly cash burn. Asset To Liability Ratio There are more short-term assets ($110.44M) than short-term liabilities ($47.27M) for RIGL. Long-term liabilities ($88.18M) are less than short-term assets ($110.44M) for RIGL. Since RIGL's debt to shareholder equity ratio (-6.83) is still negative, we do not take into account whether debt has decreased over the last five years. It is more concerning than a high ratio when RIGL's proportion of debt to equity (-6.83) is negative. Cash burn for the upcoming year ($70.75M) exceeds RIGL's cash & short-term investments ($81.64M). The profit margin for RIGL dropped by (-82.5%) in the previous year, going from (-9.9%) to (-92.4%). For at least a year, RIGL's cash & short-term investment ($81.64M) can fund its cash burn ($70.75M).

When factoring in a healthy margin of safety, RIGL ($0.83) is not considerably low (2.67%) in comparison to our estimate of its market valuation price of $0.86 based on the discounted cash flow (DCF) modeling. Scoring For RIGL Value: RIGL has a Value score of 14, which is higher than the industry average for Biotechnology. Right now, only one of RIGL's seven due diligence checks is passing. Finances: RIGL has a Financials score of 11, which is higher than the industry average for the Biotechnology sector. Only one of RIGL's seven due diligence checks is being passed. Forecast: The RIGL forecast score is 0, that is the same as the mean for the biotechnology sector. RIGL is failing 0 of 9 checks for due diligence. Performance: RIGL has a performance score of 43, which is higher than the average for the biotechnology sector. 3 from out 10 due diligence processes are being passed by RIGL. Dividend: Considering Rigel Pharmaceuticals hasn't recently paid dividends, we don't assign a score to this factor. How To Purchase Rigel Pharmaceuticals Stock Here are the six steps once more for purchasing Rigel Pharmaceuticals shares. Find out where to purchase shares in Rigel Pharmaceuticals. Open an account with a brokerage. Add your information after selecting your preferred payment method. Your brokerage account with the money. Analyze the shares of Rigel Pharmaceuticals. Purchase your RIGL product. Select whether you want to acquire RIGL stock at the spot price or at a preset price using a limit order. Get up-to-date information regarding your RIGL stock position. Make a watchlist of important changes regarding your new RIGL stock purchase.   RIGL Stock Forecast 2022 Six Wall Street analysts who follow NASDAQ: RIGL agree that the RIGL stock is a buy. Out of 6 analysts, 0 (%) suggest RIGL as a Sell, 0 (%) recommend RIGL as a Strong Sell, 1 (16.67%) recommends RIGL as a Strong Buy, 2 (33.33%) as a Buy, 3 (50%) as a Hold, and 0 (%) as a Hold Strong Sell. The revenue for Rigel Pharmaceuticals in 2022 is -$82,615,000. The average estimate of RIGL's 2022 profits from 5 Wall Street analysts is -$89,874,895, with the correct figure coming in at -$98,516,712 and the highest estimate coming in at -$81,233,078. RIGL Stock Forecast 2023 With the lowest RIGL earnings projection at -$82,961,441 and the highest RIGL statements forecast at -$36,295,631. 5 Wall Street analysts expect RIGL will earn -$57,035,991 in 2023. RIGL's revenue is expected to be $19,895,363,473 on average by 4 Wall Street analysts in 2023. The lowest RIGL revenue projection is $16,509,326,815, as well as the highest is $25,209,216,624. Analysts predict that RIGL's EPS will just be -$0.33 on average for 2023, with the lowest estimate being -$0.48 and the highest estimate being -$0.21. RIGL Stock Forecast 2024 With the lowest revenue RIGL stock forecast at $18,104,606,196 and the largest income RIGL stock forecast at $31,308,438,085, RIGL is expected to create $23,493,815,989 in sales in 2024. The estimated EPS for RIGL in 2024 will be -$0.17 (minimum: -$0.26, maximum: -$0.10). (NASDAQ: RIGL) is expected to have a ROA of -11.96%, which is worse than the predicted 13.22% average for the US Biotechnology industry. (NASDAQ: RIGL) is expected to have a dismal ROE of N/A. In the last 12 months, RIGL has not distributed any dividends. RIGL Stock Forecast 2025 12 forecasts are made for each month of 2025 for the price of Rigel Pharmaceuticals stock, with an average price prediction of $1.68, a high prognosis of $1.81, and a low prediction of $1.38. The typical Rigel Pharmaceuticals stock estimate for 2025 shows a decline from the most recent price of $2.45000004768372 of -31.53%. RIGL Stock Forecast 2027 12 RIGL stock forecast are made for each monthly of 2027 for the RIGL stock forecast for 2027 (five years), with an average prediction of $1.17, a high prognosis of $1.27, and a low prediction of $1.11. The median RIGL stock forecast for 2027 demonstrates a decrease from the most latest market o

f $2.45000004768372 of -52.27%. RIGL Stock Forecast 2030 Twelve RIGL stock forecast are made to every month of 2030 regarding the RIGL stock forecast, with an average RIGL stock forecast of $1.02, a high prognosis of $1.08, and just a low RIGL stock forecast of $0.98. From the most latest price of $2.45000004768372 to the consensus Rigel Pharmaceuticals stock forecast 2030, a -58.49% decline has occurred. RIGL Stock Forecast 2032 Four RIGL stock forecast are made for each month of 2032 for the RIGL stock forecast for 2032 (10 years), with an average prediction of $0.93, a high prediction of $0.93, and a low prediction of $0.92. The typical RIGL stock forecast for 2032 shows a decline from the most recent price of $2.45000004768372 of -62.21%.

[cavixorg]

Here's what we can say about RIGL stock. A biotechnology business called Rigel Pharmaceuticals, Inc. finds and creates small molecule medications to treat cancer, uncommon immunological illnesses, and hematologic disorders. The business provides adults with chronic immune neutropenia Tavalisse, an oral splenic inhibitor of tyrosine kinase. Additionally, it produces the drug Fostamatinib, which is currently undergoing phase III clinical trials for the treatment of COVID-19, warm autoimmune hemolytic anemia, and COVID-19 patients who are hospitalized. The company is also working on R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor, which has successfully completed a phase I clinical trial for autoimmune and inflammatory diseases. As well as R289, a verbal interleukin understanding of the mechanism kinase 1/4 inhibitor, which is in phase I randomized study for autoimmune, inflammatory, and hematology-oncology diseases. Who Owns RIGL? Institutional investors own 73.88% of Rigel Pharmaceuticals (NASDAQ: RIGL), while insiders own 15.05% and individual investors own 11.07%. The largest individual shareholder of RIGL stock is Bvf Partners L P, which holds 16.66M shares, or 9.64% of the firm. Shares of Rigel Pharmaceuticals owned by Bvf Partners L P are presently valued at $13.89M. About RIGL It has research and license contracts with AstraZeneca AB for the development and marketing of R256, an inhaled JAK inhibitor, with BerGenBio AS for the development and marketing of AXL inhibitors in oncology, with Daiichi Sankyo for the development of murine double minute 2 inhibition for solid and cytological malignancies, and with Kissei Pharmaceutical Co., Ltd. for the licensing and supply of Fostamatinib. Additionally, the business and Eli Lilly and Company have a license agreement and a strategic partnership to co-develop and market R552 for a variety of indications, including inflammatory and autoimmune illnesses and other non-CNS disease development candidates. South San Francisco, California serves as the corporate headquarters for Rigel Pharmaceuticals, Inc. What Are The Consensus Ratings And Price Objective For Rigel Pharmaceuticals? The consensus recommendation for RIGL stock, based on the present 4 hold ratings and 3 buy ratings for RIGL stock, is Hold according to the ratings that 7 analysts have issued over the past year. With a high price goal of $15.00 and a low cost target of $1.00, Rigel Pharmaceuticals' average 12 month price forecast is $3.96. NASDAQ ticker RIGL stock is used to identify Rigel Pharmaceuticals when trading on the NASDAQ. Stock quotations for Rigel Pharmaceuticals may alternatively be shown as NASDAQ: RIGL. The current share price for Rigel Pharmaceuticals is $0.83 (NASDAQ: RIGL) (as of Dec 2, 2022). (NYSE MKT: RIGL) There are now 172,836,336 shares of Rigel Pharmaceuticals outstanding. The market capitalization of Rigel Pharmaceuticals is $144.15M, with the stock now selling at $0.83 per share. On November 29, 2000, RIGL stock went public at a price of $63.99. Your return over the past 22 years if you had purchased RIGL stock at $63.99 would have been -98.7%, for just an annualized return of -17.9%. Competitors Of RIGL Verastem (VSTM), Spectrum Pharmaceuticals (SPPI), Merrimack Pharmaceuticals (MACK), Fortress Biotech (FBIO), Bolt Biotherapeutics (BOLT), Infinity Pharmaceuticals (INFI), Clovis Oncology (CLVS), Molecular Templates (MTEM), XOMA (XOMA), and Lexicon Pharmaceuticals are some of Rigel Pharmaceuticals' primary rivals (LXRX). Each of these businesses belongs to the "biotechnology" sector. Analysts favor other medical firms more than Rigel Pharmaceuticals. While the typical consensus recommendation for medical firms is Buy, Rigel Pharmaceuticals' rating is Hold. Verastem And Rigel Pharmaceuticals Verastem is outperformed by Rigel Pharmaceuticals in terms of earnings and revenue. Rigel Pharmaceuticals is currently the more cost-effective of the two stocks as it is selling at a cheaper cost ratio than Verastem.

With a beta of 0.63, Verastem's share price is predicted to be 37% less volatile than that of the S&P 500. When compared to the S&P 500, Rigel Pharmaceuticals does have a beta of 1.25, indicating that its RIGL stock price is 25% more volatile. When compared by MarketBeat users, Verastem received 150 more exceed votes than Rigel Pharmaceuticals. However, just 67.24% of individuals chose to vote for Verastem to outperform, compared to 69.61% who chose Rigel Pharmaceuticals. Institutional investors hold 58.6% of the shares of Verastem. Institutional investors now hold 80.9% of the shares of Rigel Pharmaceuticals. Insiders are the owners of 2.9% of the Verastem stock. Insiders own 6.4% of the shares of Rigel Pharmaceuticals, in contrast. A company's solid organizational ownership is a sign that hedge funds, big money managers, and endowments think it's prepared for long-term success. With a current consensus price objective of $5.00, Verastem might rise by 1,041.03%. With a $3.96 consensus price objective, Rigel Pharmaceuticals may rise by 374.91% from current levels. Analysts clearly perceive Verastem as being more favorable as Rigel Pharmaceuticals, given its higher consensus rating and more potential upside. What Date Will Rigel Pharmaceuticals Report Earnings? However, based on the report dates from the previous year, Rigel Pharmaceuticals estimates that its next earnings day will be on Tuesday, March 7, 2023. Rigel Pharmaceuticals (NASDAQ:RIGL) topped the analysts' consensus expectation of ($0.13) by $0.02 with its ($0.11) earnings per share (EPS) for the prior quarter. The reported yearly revenue for Rigel Pharmaceuticals (NASDAQ:RIGL) is $149.24 million. The reported net income for Rigel Pharmaceuticals (NASDAQ:RIGL) is -$17.91 million. Over the previous four quarters, RIGL's earnings per share were negative $0.48. Most Recent Analyst Recommendations From RIGL On December 2, 2022, Yigal Nochomovitz, a Citigroup bottom 6% analyst, increases RIGL to a solid investment rating. On November 4, 2022, Gary Nachman, a bottom 13% economist with BMO Capital, lowers their price objective for RIGL from $4 to $3 while maintaining a Buy recommendation. On August 18, 2022, Joseph Pantginis, rated bottom 10% analyst with HC Wainwright & Co., keeps RIGL with the a buy rating and increases their price objective from $7.00 to $15.00. On August 17, 2022, Do Kim, a high 33% analysts from Piper Sandler, retains RIGL with a hold recommendation and increases their price objective for the RIGL stock from $1.00 to $2.00. Financial Summary For RIGL Financial due diligence studies that RIGL passed show that it has a 70748000 cash burn. It has at least a year's worth of coverage in the form of cash and short-term investments. On the RIGL cash balance, short-term assets outnumber long-term liabilities. On the RIGL accounting records, short-term assets exceed short-term liabilities. Financial Due Diligence Tests that Fail: In the previous year, RIGL's profit margin decreased from -9.9% to -92.4%. The RIGL ratio of debt to equity is negative at -6.83. The total debt of RIGL is still negative. RIGL has $81.64M in short-term investments and cash. This is insufficient to fund its $70.75M yearly cash burn. Asset To Liability Ratio There are more short-term assets ($110.44M) than short-term liabilities ($47.27M) for RIGL. Long-term liabilities ($88.18M) are less than short-term assets ($110.44M) for RIGL. Since RIGL's debt to shareholder equity ratio (-6.83) is still negative, we do not take into account whether debt has decreased over the last five years. It is more concerning than a high ratio when RIGL's proportion of debt to equity (-6.83) is negative. Cash burn for the upcoming year ($70.75M) exceeds RIGL's cash & short-term investments ($81.64M). The profit margin for RIGL dropped by (-82.5%) in the previous year, going from (-9.9%) to (-92.4%). For at least a year, RIGL's cash & short-term investment ($81.64M) can fund its cash burn ($70.75M).

When factoring in a healthy margin of safety, RIGL ($0.83) is not considerably low (2.67%) in comparison to our estimate of its market valuation price of $0.86 based on the discounted cash flow (DCF) modeling. Scoring For RIGL Value: RIGL has a Value score of 14, which is higher than the industry average for Biotechnology. Right now, only one of RIGL's seven due diligence checks is passing. Finances: RIGL has a Financials score of 11, which is higher than the industry average for the Biotechnology sector. Only one of RIGL's seven due diligence checks is being passed. Forecast: The RIGL forecast score is 0, that is the same as the mean for the biotechnology sector. RIGL is failing 0 of 9 checks for due diligence. Performance: RIGL has a performance score of 43, which is higher than the average for the biotechnology sector. 3 from out 10 due diligence processes are being passed by RIGL. Dividend: Considering Rigel Pharmaceuticals hasn't recently paid dividends, we don't assign a score to this factor. How To Purchase Rigel Pharmaceuticals Stock Here are the six steps once more for purchasing Rigel Pharmaceuticals shares. Find out where to purchase shares in Rigel Pharmaceuticals. Open an account with a brokerage. Add your information after selecting your preferred payment method. Your brokerage account with the money. Analyze the shares of Rigel Pharmaceuticals. Purchase your RIGL product. Select whether you want to acquire RIGL stock at the spot price or at a preset price using a limit order. Get up-to-date information regarding your RIGL stock position. Make a watchlist of important changes regarding your new RIGL stock purchase.   RIGL Stock Forecast 2022 Six Wall Street analysts who follow NASDAQ: RIGL agree that the RIGL stock is a buy. Out of 6 analysts, 0 (%) suggest RIGL as a Sell, 0 (%) recommend RIGL as a Strong Sell, 1 (16.67%) recommends RIGL as a Strong Buy, 2 (33.33%) as a Buy, 3 (50%) as a Hold, and 0 (%) as a Hold Strong Sell. The revenue for Rigel Pharmaceuticals in 2022 is -$82,615,000. The average estimate of RIGL's 2022 profits from 5 Wall Street analysts is -$89,874,895, with the correct figure coming in at -$98,516,712 and the highest estimate coming in at -$81,233,078. RIGL Stock Forecast 2023 With the lowest RIGL earnings projection at -$82,961,441 and the highest RIGL statements forecast at -$36,295,631. 5 Wall Street analysts expect RIGL will earn -$57,035,991 in 2023. RIGL's revenue is expected to be $19,895,363,473 on average by 4 Wall Street analysts in 2023. The lowest RIGL revenue projection is $16,509,326,815, as well as the highest is $25,209,216,624. Analysts predict that RIGL's EPS will just be -$0.33 on average for 2023, with the lowest estimate being -$0.48 and the highest estimate being -$0.21. RIGL Stock Forecast 2024 With the lowest revenue RIGL stock forecast at $18,104,606,196 and the largest income RIGL stock forecast at $31,308,438,085, RIGL is expected to create $23,493,815,989 in sales in 2024. The estimated EPS for RIGL in 2024 will be -$0.17 (minimum: -$0.26, maximum: -$0.10). (NASDAQ: RIGL) is expected to have a ROA of -11.96%, which is worse than the predicted 13.22% average for the US Biotechnology industry. (NASDAQ: RIGL) is expected to have a dismal ROE of N/A. In the last 12 months, RIGL has not distributed any dividends. RIGL Stock Forecast 2025 12 forecasts are made for each month of 2025 for the price of Rigel Pharmaceuticals stock, with an average price prediction of $1.68, a high prognosis of $1.81, and a low prediction of $1.38. The typical Rigel Pharmaceuticals stock estimate for 2025 shows a decline from the most recent price of $2.45000004768372 of -31.53%. RIGL Stock Forecast 2027 12 RIGL stock forecast are made for each monthly of 2027 for the RIGL stock forecast for 2027 (five years), with an average prediction of $1.17, a high prognosis of $1.27, and a low prediction of $1.11. The median RIGL stock forecast for 2027 demonstrates a decrease from the most latest market o

f $2.45000004768372 of -52.27%. RIGL Stock Forecast 2030 Twelve RIGL stock forecast are made to every month of 2030 regarding the RIGL stock forecast, with an average RIGL stock forecast of $1.02, a high prognosis of $1.08, and just a low RIGL stock forecast of $0.98. From the most latest price of $2.45000004768372 to the consensus Rigel Pharmaceuticals stock forecast 2030, a -58.49% decline has occurred. RIGL Stock Forecast 2032 Four RIGL stock forecast are made for each month of 2032 for the RIGL stock forecast for 2032 (10 years), with an average prediction of $0.93, a high prediction of $0.93, and a low prediction of $0.92. The typical RIGL stock forecast for 2032 shows a decline from the most recent price of $2.45000004768372 of -62.21%.

[databridgemarketresearchblog]

Acquired (Autoimmune) Hemolytic Anemia Market 2020 will Change the Future | Global Players - Novartis AG, Sanofi, Dr. Reddy’s Laboratories Ltd, Zydus Cadila, Concord Biotech, Alkem Labs

Global acquired (autoimmune) hemolytic anemia market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period.

Get Exclusive Sample Copy of This Report Here https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-acquired-autoimmune-hemolytic-anemia-market

The market dynamics study of this Acquired (Autoimmune) Hemolytic Anemia Market business research report demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. It also studies the key markets and mentions different regions i.e. the geographical spread of the business. Under competitive market share evaluation, this document suggests that the key players dominate the operations in the industry attributable to their strong geographical reach & huge production facilities. The major players operating in the Acquired (Autoimmune) Hemolytic Anemia Market are in strong competition in terms of technology, innovation, and pricing.

The major players covered in the global acquired (autoimmune) hemolytic anemia market are Novartis AG, Sanofi, Dr. Reddy’s Laboratories Ltd, Zydus Cadila, Concord Biotech, Alkem Labs, F. Hoffmann-La Roche Ltd, Baxter and others.

Read Complete Details with TOC Here https://www.databridgemarketresearch.com/toc/?dbmr=global-acquired-autoimmune-hemolytic-anemia-market

Market Analysis and Insights: Global Acquired (Autoimmune) Hemolytic Anemia Market

Rise in prevalence of certain tumors and autoimmune disorders which can increase the risk of hemolytic anemia diseases and unmet medical needs are responsible for growth of acquired (autoimmune) hemolytic anemia market. Moreover, new products under pipeline may also boost the growth of this market. However, scarcity of approved products for treatment may restrain the market growth.

Acquired (autoimmune) hemolytic anemia which is also known as idiopathic autoimmune hemolytic is a rare autoimmune disorder, in which our body starts producing anti-bodies against our red blood cells. Acquired (autoimmune) hemolytic anemia market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Acquired (Autoimmune) Hemolytic Anemia Market Scope and Market Size

Acquired (autoimmune) hemolytic anemia market is segmented on the basis of types, treatment, diagnosis, end-users and distribution channel.

On the basis of types, the global acquired (autoimmune) hemolytic anemia market is segmented into warm autoimmune induced hemolytic anemia, cold agglutinin disease (CAD) and others.

On the basis of treatment, the global acquired (autoimmune) hemolytic anemia market is segmented into medication, blood transfusion, surgeries and others. Medication can be further segmented into corticosteroids, immunosuppressive agents and others.

On the basis of diagnosis, the global acquired (autoimmune) hemolytic anemia market is segmented into blood tests, coombs test and others.

On the basis of end-users, the global acquired (autoimmune) hemolytic anemia market is segmented into hospitals, homecare, specialty clinics and others.

On the basis of distribution channel, the global acquired (autoimmune) hemolytic anemia market can be segmented into hospital pharmacy, online pharmacy and retail pharmacy.

Global Acquired (Autoimmune) Hemolytic Anemia Market Country Level Analysis

Acquired (autoimmune) hemolytic anemia market is analyzed and market size information is provided by country, types, treatment, diagnosis, end-users and distribution channel as referenced above.

The countries covered in the global   acquired (autoimmune) hemolytic anemia  market  report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

Asia-Pacific is expected to contribute for the largest share in the market the market due to the increasing prevalence of autoimmune disorders. Europe is considered to hold bright growth prospects in the coming years with growing investment in healthcare infrastructure. North America region is likely to lead the market for acquired (autoimmune) hemolytic anemia market due to focus of global key market players on novel technology.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Global acquired (autoimmune) hemolytic anemia market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Acquired (Autoimmune) Hemolytic Anemia Market Share Analysis

Global acquired (autoimmune) hemolytic anemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global acquired (autoimmune) hemolytic anemia market.

Customization Available: Global Acquired (Autoimmune) Hemolytic Anemia Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

To Get This Report at an Attractive Cost, Click Here https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-acquired-autoimmune-hemolytic-anemia-market

About Data Bridge Market Research:

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475 Mail: Corporatesales@databridgemarketresearch.com

[anjrawat]

Warm Autoimmune Hemolytic Anemia Market Forecast and Pipeline Analysis

In 2017, as per the estimates by DelveInsight, Warm Autoimmune Haemolytic Anemia had affected 82,045 people approximately in the 7MM. WAIHA affects around 1 in 35,000 people in North America. With a population of about 57 crores, WAIHA is a cause of distress to many living in that continent only, let alone worldwide. 

As of now,  there exists no FDA-approved therapy in the Warm autoimmune hemolytic anemia market for patients to rely on. 

The current Warm Autoimmune Haemolytic Anemia market is positively evolving and will continue to grow at a CAGR of 15.9% in the 7MM by 2030 estimates DelveInsight Warm autoimmune hemolytic anemia forecast analysis for the period 2019-2030.

Improvement in the diagnosis methodologies and incremental healthcare spending across the world are going to add to the Warm Autoimmune Hemolytic Anemia market leading towards the development of new treatment therapies, addressed challenges, and a better approach towards treating Warm autoimmune hemolytic anemia treatment.

https://www.delveinsight.com/blog/warm-autoimmune-hemolytic-anemia-market/

[stocklivemarket]

Here's what we can say about RIGL stock. A biotechnology business called Rigel Pharmaceuticals, Inc. finds and creates small molecule medications to treat cancer, uncommon immunological illnesses, and hematologic disorders. The business provides adults with chronic immune neutropenia Tavalisse, an oral splenic inhibitor of tyrosine kinase. Additionally, it produces the drug Fostamatinib, which is currently undergoing phase III clinical trials for the treatment of COVID-19, warm autoimmune hemolytic anemia, and COVID-19 patients who are hospitalized. The company is also working on R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor, which has successfully completed a phase I clinical trial for autoimmune and inflammatory diseases. As well as R289, a verbal interleukin understanding of the mechanism kinase 1/4 inhibitor, which is in phase I randomized study for autoimmune, inflammatory, and hematology-oncology diseases. Who Owns RIGL? Institutional investors own 73.88% of Rigel Pharmaceuticals (NASDAQ: RIGL), while insiders own 15.05% and individual investors own 11.07%. The largest individual shareholder of RIGL stock is Bvf Partners L P, which holds 16.66M shares, or 9.64% of the firm. Shares of Rigel Pharmaceuticals owned by Bvf Partners L P are presently valued at $13.89M. About RIGL It has research and license contracts with AstraZeneca AB for the development and marketing of R256, an inhaled JAK inhibitor, with BerGenBio AS for the development and marketing of AXL inhibitors in oncology, with Daiichi Sankyo for the development of murine double minute 2 inhibition for solid and cytological malignancies, and with Kissei Pharmaceutical Co., Ltd. for the licensing and supply of Fostamatinib. Additionally, the business and Eli Lilly and Company have a license agreement and a strategic partnership to co-develop and market R552 for a variety of indications, including inflammatory and autoimmune illnesses and other non-CNS disease development candidates. South San Francisco, California serves as the corporate headquarters for Rigel Pharmaceuticals, Inc. What Are The Consensus Ratings And Price Objective For Rigel Pharmaceuticals? The consensus recommendation for RIGL stock, based on the present 4 hold ratings and 3 buy ratings for RIGL stock, is Hold according to the ratings that 7 analysts have issued over the past year. With a high price goal of $15.00 and a low cost target of $1.00, Rigel Pharmaceuticals' average 12 month price forecast is $3.96. NASDAQ ticker RIGL stock is used to identify Rigel Pharmaceuticals when trading on the NASDAQ. Stock quotations for Rigel Pharmaceuticals may alternatively be shown as NASDAQ: RIGL. The current share price for Rigel Pharmaceuticals is $0.83 (NASDAQ: RIGL) (as of Dec 2, 2022). (NYSE MKT: RIGL) There are now 172,836,336 shares of Rigel Pharmaceuticals outstanding. The market capitalization of Rigel Pharmaceuticals is $144.15M, with the stock now selling at $0.83 per share. On November 29, 2000, RIGL stock went public at a price of $63.99. Your return over the past 22 years if you had purchased RIGL stock at $63.99 would have been -98.7%, for just an annualized return of -17.9%. Competitors Of RIGL Verastem (VSTM), Spectrum Pharmaceuticals (SPPI), Merrimack Pharmaceuticals (MACK), Fortress Biotech (FBIO), Bolt Biotherapeutics (BOLT), Infinity Pharmaceuticals (INFI), Clovis Oncology (CLVS), Molecular Templates (MTEM), XOMA (XOMA), and Lexicon Pharmaceuticals are some of Rigel Pharmaceuticals' primary rivals (LXRX). Each of these businesses belongs to the "biotechnology" sector. Analysts favor other medical firms more than Rigel Pharmaceuticals. While the typical consensus recommendation for medical firms is Buy, Rigel Pharmaceuticals' rating is Hold. Verastem And Rigel Pharmaceuticals Verastem is outperformed by Rigel Pharmaceuticals in terms of earnings and revenue. Rigel Pharmaceuticals is currently the more cost-effective of the two stocks as it is selling at a cheaper cost ratio than Verastem.

With a beta of 0.63, Verastem's share price is predicted to be 37% less volatile than that of the S&P 500. When compared to the S&P 500, Rigel Pharmaceuticals does have a beta of 1.25, indicating that its RIGL stock price is 25% more volatile. When compared by MarketBeat users, Verastem received 150 more exceed votes than Rigel Pharmaceuticals. However, just 67.24% of individuals chose to vote for Verastem to outperform, compared to 69.61% who chose Rigel Pharmaceuticals. Institutional investors hold 58.6% of the shares of Verastem. Institutional investors now hold 80.9% of the shares of Rigel Pharmaceuticals. Insiders are the owners of 2.9% of the Verastem stock. Insiders own 6.4% of the shares of Rigel Pharmaceuticals, in contrast. A company's solid organizational ownership is a sign that hedge funds, big money managers, and endowments think it's prepared for long-term success. With a current consensus price objective of $5.00, Verastem might rise by 1,041.03%. With a $3.96 consensus price objective, Rigel Pharmaceuticals may rise by 374.91% from current levels. Analysts clearly perceive Verastem as being more favorable as Rigel Pharmaceuticals, given its higher consensus rating and more potential upside. What Date Will Rigel Pharmaceuticals Report Earnings? However, based on the report dates from the previous year, Rigel Pharmaceuticals estimates that its next earnings day will be on Tuesday, March 7, 2023. Rigel Pharmaceuticals (NASDAQ:RIGL) topped the analysts' consensus expectation of ($0.13) by $0.02 with its ($0.11) earnings per share (EPS) for the prior quarter. The reported yearly revenue for Rigel Pharmaceuticals (NASDAQ:RIGL) is $149.24 million. The reported net income for Rigel Pharmaceuticals (NASDAQ:RIGL) is -$17.91 million. Over the previous four quarters, RIGL's earnings per share were negative $0.48. Most Recent Analyst Recommendations From RIGL On December 2, 2022, Yigal Nochomovitz, a Citigroup bottom 6% analyst, increases RIGL to a solid investment rating. On November 4, 2022, Gary Nachman, a bottom 13% economist with BMO Capital, lowers their price objective for RIGL from $4 to $3 while maintaining a Buy recommendation. On August 18, 2022, Joseph Pantginis, rated bottom 10% analyst with HC Wainwright & Co., keeps RIGL with the a buy rating and increases their price objective from $7.00 to $15.00. On August 17, 2022, Do Kim, a high 33% analysts from Piper Sandler, retains RIGL with a hold recommendation and increases their price objective for the RIGL stock from $1.00 to $2.00. Financial Summary For RIGL Financial due diligence studies that RIGL passed show that it has a 70748000 cash burn. It has at least a year's worth of coverage in the form of cash and short-term investments. On the RIGL cash balance, short-term assets outnumber long-term liabilities. On the RIGL accounting records, short-term assets exceed short-term liabilities. Financial Due Diligence Tests that Fail: In the previous year, RIGL's profit margin decreased from -9.9% to -92.4%. The RIGL ratio of debt to equity is negative at -6.83. The total debt of RIGL is still negative. RIGL has $81.64M in short-term investments and cash. This is insufficient to fund its $70.75M yearly cash burn. Asset To Liability Ratio There are more short-term assets ($110.44M) than short-term liabilities ($47.27M) for RIGL. Long-term liabilities ($88.18M) are less than short-term assets ($110.44M) for RIGL. Since RIGL's debt to shareholder equity ratio (-6.83) is still negative, we do not take into account whether debt has decreased over the last five years. It is more concerning than a high ratio when RIGL's proportion of debt to equity (-6.83) is negative. Cash burn for the upcoming year ($70.75M) exceeds RIGL's cash & short-term investments ($81.64M). The profit margin for RIGL dropped by (-82.5%) in the previous year, going from (-9.9%) to (-92.4%). For at least a year, RIGL's cash & short-term investment ($81.64M) can fund its cash burn ($70.75M).

When factoring in a healthy margin of safety, RIGL ($0.83) is not considerably low (2.67%) in comparison to our estimate of its market valuation price of $0.86 based on the discounted cash flow (DCF) modeling. Scoring For RIGL Value: RIGL has a Value score of 14, which is higher than the industry average for Biotechnology. Right now, only one of RIGL's seven due diligence checks is passing. Finances: RIGL has a Financials score of 11, which is higher than the industry average for the Biotechnology sector. Only one of RIGL's seven due diligence checks is being passed. Forecast: The RIGL forecast score is 0, that is the same as the mean for the biotechnology sector. RIGL is failing 0 of 9 checks for due diligence. Performance: RIGL has a performance score of 43, which is higher than the average for the biotechnology sector. 3 from out 10 due diligence processes are being passed by RIGL. Dividend: Considering Rigel Pharmaceuticals hasn't recently paid dividends, we don't assign a score to this factor. How To Purchase Rigel Pharmaceuticals Stock Here are the six steps once more for purchasing Rigel Pharmaceuticals shares. Find out where to purchase shares in Rigel Pharmaceuticals. Open an account with a brokerage. Add your information after selecting your preferred payment method. Your brokerage account with the money. Analyze the shares of Rigel Pharmaceuticals. Purchase your RIGL product. Select whether you want to acquire RIGL stock at the spot price or at a preset price using a limit order. Get up-to-date information regarding your RIGL stock position. Make a watchlist of important changes regarding your new RIGL stock purchase.   RIGL Stock Forecast 2022 Six Wall Street analysts who follow NASDAQ: RIGL agree that the RIGL stock is a buy. Out of 6 analysts, 0 (%) suggest RIGL as a Sell, 0 (%) recommend RIGL as a Strong Sell, 1 (16.67%) recommends RIGL as a Strong Buy, 2 (33.33%) as a Buy, 3 (50%) as a Hold, and 0 (%) as a Hold Strong Sell. The revenue for Rigel Pharmaceuticals in 2022 is -$82,615,000. The average estimate of RIGL's 2022 profits from 5 Wall Street analysts is -$89,874,895, with the correct figure coming in at -$98,516,712 and the highest estimate coming in at -$81,233,078. RIGL Stock Forecast 2023 With the lowest RIGL earnings projection at -$82,961,441 and the highest RIGL statements forecast at -$36,295,631. 5 Wall Street analysts expect RIGL will earn -$57,035,991 in 2023. RIGL's revenue is expected to be $19,895,363,473 on average by 4 Wall Street analysts in 2023. The lowest RIGL revenue projection is $16,509,326,815, as well as the highest is $25,209,216,624. Analysts predict that RIGL's EPS will just be -$0.33 on average for 2023, with the lowest estimate being -$0.48 and the highest estimate being -$0.21. RIGL Stock Forecast 2024 With the lowest revenue RIGL stock forecast at $18,104,606,196 and the largest income RIGL stock forecast at $31,308,438,085, RIGL is expected to create $23,493,815,989 in sales in 2024. The estimated EPS for RIGL in 2024 will be -$0.17 (minimum: -$0.26, maximum: -$0.10). (NASDAQ: RIGL) is expected to have a ROA of -11.96%, which is worse than the predicted 13.22% average for the US Biotechnology industry. (NASDAQ: RIGL) is expected to have a dismal ROE of N/A. In the last 12 months, RIGL has not distributed any dividends. RIGL Stock Forecast 2025 12 forecasts are made for each month of 2025 for the price of Rigel Pharmaceuticals stock, with an average price prediction of $1.68, a high prognosis of $1.81, and a low prediction of $1.38. The typical Rigel Pharmaceuticals stock estimate for 2025 shows a decline from the most recent price of $2.45000004768372 of -31.53%. RIGL Stock Forecast 2027 12 RIGL stock forecast are made for each monthly of 2027 for the RIGL stock forecast for 2027 (five years), with an average prediction of $1.17, a high prognosis of $1.27, and a low prediction of $1.11. The median RIGL stock forecast for 2027 demonstrates a decrease from the most latest market o

f $2.45000004768372 of -52.27%. RIGL Stock Forecast 2030 Twelve RIGL stock forecast are made to every month of 2030 regarding the RIGL stock forecast, with an average RIGL stock forecast of $1.02, a high prognosis of $1.08, and just a low RIGL stock forecast of $0.98. From the most latest price of $2.45000004768372 to the consensus Rigel Pharmaceuticals stock forecast 2030, a -58.49% decline has occurred. RIGL Stock Forecast 2032 Four RIGL stock forecast are made for each month of 2032 for the RIGL stock forecast for 2032 (10 years), with an average prediction of $0.93, a high prediction of $0.93, and a low prediction of $0.92. The typical RIGL stock forecast for 2032 shows a decline from the most recent price of $2.45000004768372 of -62.21%.

[stocklivemarket]

Here's what we can say about RIGL stock. A biotechnology business called Rigel Pharmaceuticals, Inc. finds and creates small molecule medications to treat cancer, uncommon immunological illnesses, and hematologic disorders. The business provides adults with chronic immune neutropenia Tavalisse, an oral splenic inhibitor of tyrosine kinase. Additionally, it produces the drug Fostamatinib, which is currently undergoing phase III clinical trials for the treatment of COVID-19, warm autoimmune hemolytic anemia, and COVID-19 patients who are hospitalized. The company is also working on R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor, which has successfully completed a phase I clinical trial for autoimmune and inflammatory diseases. As well as R289, a verbal interleukin understanding of the mechanism kinase 1/4 inhibitor, which is in phase I randomized study for autoimmune, inflammatory, and hematology-oncology diseases. Who Owns RIGL? Institutional investors own 73.88% of Rigel Pharmaceuticals (NASDAQ: RIGL), while insiders own 15.05% and individual investors own 11.07%. The largest individual shareholder of RIGL stock is Bvf Partners L P, which holds 16.66M shares, or 9.64% of the firm. Shares of Rigel Pharmaceuticals owned by Bvf Partners L P are presently valued at $13.89M. About RIGL It has research and license contracts with AstraZeneca AB for the development and marketing of R256, an inhaled JAK inhibitor, with BerGenBio AS for the development and marketing of AXL inhibitors in oncology, with Daiichi Sankyo for the development of murine double minute 2 inhibition for solid and cytological malignancies, and with Kissei Pharmaceutical Co., Ltd. for the licensing and supply of Fostamatinib. Additionally, the business and Eli Lilly and Company have a license agreement and a strategic partnership to co-develop and market R552 for a variety of indications, including inflammatory and autoimmune illnesses and other non-CNS disease development candidates. South San Francisco, California serves as the corporate headquarters for Rigel Pharmaceuticals, Inc. What Are The Consensus Ratings And Price Objective For Rigel Pharmaceuticals? The consensus recommendation for RIGL stock, based on the present 4 hold ratings and 3 buy ratings for RIGL stock, is Hold according to the ratings that 7 analysts have issued over the past year. With a high price goal of $15.00 and a low cost target of $1.00, Rigel Pharmaceuticals' average 12 month price forecast is $3.96. NASDAQ ticker RIGL stock is used to identify Rigel Pharmaceuticals when trading on the NASDAQ. Stock quotations for Rigel Pharmaceuticals may alternatively be shown as NASDAQ: RIGL. The current share price for Rigel Pharmaceuticals is $0.83 (NASDAQ: RIGL) (as of Dec 2, 2022). (NYSE MKT: RIGL) There are now 172,836,336 shares of Rigel Pharmaceuticals outstanding. The market capitalization of Rigel Pharmaceuticals is $144.15M, with the stock now selling at $0.83 per share. On November 29, 2000, RIGL stock went public at a price of $63.99. Your return over the past 22 years if you had purchased RIGL stock at $63.99 would have been -98.7%, for just an annualized return of -17.9%. Competitors Of RIGL Verastem (VSTM), Spectrum Pharmaceuticals (SPPI), Merrimack Pharmaceuticals (MACK), Fortress Biotech (FBIO), Bolt Biotherapeutics (BOLT), Infinity Pharmaceuticals (INFI), Clovis Oncology (CLVS), Molecular Templates (MTEM), XOMA (XOMA), and Lexicon Pharmaceuticals are some of Rigel Pharmaceuticals' primary rivals (LXRX). Each of these businesses belongs to the "biotechnology" sector. Analysts favor other medical firms more than Rigel Pharmaceuticals. While the typical consensus recommendation for medical firms is Buy, Rigel Pharmaceuticals' rating is Hold. Verastem And Rigel Pharmaceuticals Verastem is outperformed by Rigel Pharmaceuticals in terms of earnings and revenue. Rigel Pharmaceuticals is currently the more cost-effective of the two stocks as it is selling at a cheaper cost ratio than Verastem.

With a beta of 0.63, Verastem's share price is predicted to be 37% less volatile than that of the S&P 500. When compared to the S&P 500, Rigel Pharmaceuticals does have a beta of 1.25, indicating that its RIGL stock price is 25% more volatile. When compared by MarketBeat users, Verastem received 150 more exceed votes than Rigel Pharmaceuticals. However, just 67.24% of individuals chose to vote for Verastem to outperform, compared to 69.61% who chose Rigel Pharmaceuticals. Institutional investors hold 58.6% of the shares of Verastem. Institutional investors now hold 80.9% of the shares of Rigel Pharmaceuticals. Insiders are the owners of 2.9% of the Verastem stock. Insiders own 6.4% of the shares of Rigel Pharmaceuticals, in contrast. A company's solid organizational ownership is a sign that hedge funds, big money managers, and endowments think it's prepared for long-term success. With a current consensus price objective of $5.00, Verastem might rise by 1,041.03%. With a $3.96 consensus price objective, Rigel Pharmaceuticals may rise by 374.91% from current levels. Analysts clearly perceive Verastem as being more favorable as Rigel Pharmaceuticals, given its higher consensus rating and more potential upside. What Date Will Rigel Pharmaceuticals Report Earnings? However, based on the report dates from the previous year, Rigel Pharmaceuticals estimates that its next earnings day will be on Tuesday, March 7, 2023. Rigel Pharmaceuticals (NASDAQ:RIGL) topped the analysts' consensus expectation of ($0.13) by $0.02 with its ($0.11) earnings per share (EPS) for the prior quarter. The reported yearly revenue for Rigel Pharmaceuticals (NASDAQ:RIGL) is $149.24 million. The reported net income for Rigel Pharmaceuticals (NASDAQ:RIGL) is -$17.91 million. Over the previous four quarters, RIGL's earnings per share were negative $0.48. Most Recent Analyst Recommendations From RIGL On December 2, 2022, Yigal Nochomovitz, a Citigroup bottom 6% analyst, increases RIGL to a solid investment rating. On November 4, 2022, Gary Nachman, a bottom 13% economist with BMO Capital, lowers their price objective for RIGL from $4 to $3 while maintaining a Buy recommendation. On August 18, 2022, Joseph Pantginis, rated bottom 10% analyst with HC Wainwright & Co., keeps RIGL with the a buy rating and increases their price objective from $7.00 to $15.00. On August 17, 2022, Do Kim, a high 33% analysts from Piper Sandler, retains RIGL with a hold recommendation and increases their price objective for the RIGL stock from $1.00 to $2.00. Financial Summary For RIGL Financial due diligence studies that RIGL passed show that it has a 70748000 cash burn. It has at least a year's worth of coverage in the form of cash and short-term investments. On the RIGL cash balance, short-term assets outnumber long-term liabilities. On the RIGL accounting records, short-term assets exceed short-term liabilities. Financial Due Diligence Tests that Fail: In the previous year, RIGL's profit margin decreased from -9.9% to -92.4%. The RIGL ratio of debt to equity is negative at -6.83. The total debt of RIGL is still negative. RIGL has $81.64M in short-term investments and cash. This is insufficient to fund its $70.75M yearly cash burn. Asset To Liability Ratio There are more short-term assets ($110.44M) than short-term liabilities ($47.27M) for RIGL. Long-term liabilities ($88.18M) are less than short-term assets ($110.44M) for RIGL. Since RIGL's debt to shareholder equity ratio (-6.83) is still negative, we do not take into account whether debt has decreased over the last five years. It is more concerning than a high ratio when RIGL's proportion of debt to equity (-6.83) is negative. Cash burn for the upcoming year ($70.75M) exceeds RIGL's cash & short-term investments ($81.64M). The profit margin for RIGL dropped by (-82.5%) in the previous year, going from (-9.9%) to (-92.4%). For at least a year, RIGL's cash & short-term investment ($81.64M) can fund its cash burn ($70.75M).

When factoring in a healthy margin of safety, RIGL ($0.83) is not considerably low (2.67%) in comparison to our estimate of its market valuation price of $0.86 based on the discounted cash flow (DCF) modeling. Scoring For RIGL Value: RIGL has a Value score of 14, which is higher than the industry average for Biotechnology. Right now, only one of RIGL's seven due diligence checks is passing. Finances: RIGL has a Financials score of 11, which is higher than the industry average for the Biotechnology sector. Only one of RIGL's seven due diligence checks is being passed. Forecast: The RIGL forecast score is 0, that is the same as the mean for the biotechnology sector. RIGL is failing 0 of 9 checks for due diligence. Performance: RIGL has a performance score of 43, which is higher than the average for the biotechnology sector. 3 from out 10 due diligence processes are being passed by RIGL. Dividend: Considering Rigel Pharmaceuticals hasn't recently paid dividends, we don't assign a score to this factor. How To Purchase Rigel Pharmaceuticals Stock Here are the six steps once more for purchasing Rigel Pharmaceuticals shares. Find out where to purchase shares in Rigel Pharmaceuticals. Open an account with a brokerage. Add your information after selecting your preferred payment method. Your brokerage account with the money. Analyze the shares of Rigel Pharmaceuticals. Purchase your RIGL product. Select whether you want to acquire RIGL stock at the spot price or at a preset price using a limit order. Get up-to-date information regarding your RIGL stock position. Make a watchlist of important changes regarding your new RIGL stock purchase.   RIGL Stock Forecast 2022 Six Wall Street analysts who follow NASDAQ: RIGL agree that the RIGL stock is a buy. Out of 6 analysts, 0 (%) suggest RIGL as a Sell, 0 (%) recommend RIGL as a Strong Sell, 1 (16.67%) recommends RIGL as a Strong Buy, 2 (33.33%) as a Buy, 3 (50%) as a Hold, and 0 (%) as a Hold Strong Sell. The revenue for Rigel Pharmaceuticals in 2022 is -$82,615,000. The average estimate of RIGL's 2022 profits from 5 Wall Street analysts is -$89,874,895, with the correct figure coming in at -$98,516,712 and the highest estimate coming in at -$81,233,078. RIGL Stock Forecast 2023 With the lowest RIGL earnings projection at -$82,961,441 and the highest RIGL statements forecast at -$36,295,631. 5 Wall Street analysts expect RIGL will earn -$57,035,991 in 2023. RIGL's revenue is expected to be $19,895,363,473 on average by 4 Wall Street analysts in 2023. The lowest RIGL revenue projection is $16,509,326,815, as well as the highest is $25,209,216,624. Analysts predict that RIGL's EPS will just be -$0.33 on average for 2023, with the lowest estimate being -$0.48 and the highest estimate being -$0.21. RIGL Stock Forecast 2024 With the lowest revenue RIGL stock forecast at $18,104,606,196 and the largest income RIGL stock forecast at $31,308,438,085, RIGL is expected to create $23,493,815,989 in sales in 2024. The estimated EPS for RIGL in 2024 will be -$0.17 (minimum: -$0.26, maximum: -$0.10). (NASDAQ: RIGL) is expected to have a ROA of -11.96%, which is worse than the predicted 13.22% average for the US Biotechnology industry. (NASDAQ: RIGL) is expected to have a dismal ROE of N/A. In the last 12 months, RIGL has not distributed any dividends. RIGL Stock Forecast 2025 12 forecasts are made for each month of 2025 for the price of Rigel Pharmaceuticals stock, with an average price prediction of $1.68, a high prognosis of $1.81, and a low prediction of $1.38. The typical Rigel Pharmaceuticals stock estimate for 2025 shows a decline from the most recent price of $2.45000004768372 of -31.53%. RIGL Stock Forecast 2027 12 RIGL stock forecast are made for each monthly of 2027 for the RIGL stock forecast for 2027 (five years), with an average prediction of $1.17, a high prognosis of $1.27, and a low prediction of $1.11. The median RIGL stock forecast for 2027 demonstrates a decrease from the most latest market o

f $2.45000004768372 of -52.27%. RIGL Stock Forecast 2030 Twelve RIGL stock forecast are made to every month of 2030 regarding the RIGL stock forecast, with an average RIGL stock forecast of $1.02, a high prognosis of $1.08, and just a low RIGL stock forecast of $0.98. From the most latest price of $2.45000004768372 to the consensus Rigel Pharmaceuticals stock forecast 2030, a -58.49% decline has occurred. RIGL Stock Forecast 2032 Four RIGL stock forecast are made for each month of 2032 for the RIGL stock forecast for 2032 (10 years), with an average prediction of $0.93, a high prediction of $0.93, and a low prediction of $0.92. The typical RIGL stock forecast for 2032 shows a decline from the most recent price of $2.45000004768372 of -62.21%.

[cavixorg]

Here's what we can say about RIGL stock. A biotechnology business called Rigel Pharmaceuticals, Inc. finds and creates small molecule medications to treat cancer, uncommon immunological illnesses, and hematologic disorders. The business provides adults with chronic immune neutropenia Tavalisse, an oral splenic inhibitor of tyrosine kinase. Additionally, it produces the drug Fostamatinib, which is currently undergoing phase III clinical trials for the treatment of COVID-19, warm autoimmune hemolytic anemia, and COVID-19 patients who are hospitalized. The company is also working on R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor, which has successfully completed a phase I clinical trial for autoimmune and inflammatory diseases. As well as R289, a verbal interleukin understanding of the mechanism kinase 1/4 inhibitor, which is in phase I randomized study for autoimmune, inflammatory, and hematology-oncology diseases. Who Owns RIGL? Institutional investors own 73.88% of Rigel Pharmaceuticals (NASDAQ: RIGL), while insiders own 15.05% and individual investors own 11.07%. The largest individual shareholder of RIGL stock is Bvf Partners L P, which holds 16.66M shares, or 9.64% of the firm. Shares of Rigel Pharmaceuticals owned by Bvf Partners L P are presently valued at $13.89M. About RIGL It has research and license contracts with AstraZeneca AB for the development and marketing of R256, an inhaled JAK inhibitor, with BerGenBio AS for the development and marketing of AXL inhibitors in oncology, with Daiichi Sankyo for the development of murine double minute 2 inhibition for solid and cytological malignancies, and with Kissei Pharmaceutical Co., Ltd. for the licensing and supply of Fostamatinib. Additionally, the business and Eli Lilly and Company have a license agreement and a strategic partnership to co-develop and market R552 for a variety of indications, including inflammatory and autoimmune illnesses and other non-CNS disease development candidates. South San Francisco, California serves as the corporate headquarters for Rigel Pharmaceuticals, Inc. What Are The Consensus Ratings And Price Objective For Rigel Pharmaceuticals? The consensus recommendation for RIGL stock, based on the present 4 hold ratings and 3 buy ratings for RIGL stock, is Hold according to the ratings that 7 analysts have issued over the past year. With a high price goal of $15.00 and a low cost target of $1.00, Rigel Pharmaceuticals' average 12 month price forecast is $3.96. NASDAQ ticker RIGL stock is used to identify Rigel Pharmaceuticals when trading on the NASDAQ. Stock quotations for Rigel Pharmaceuticals may alternatively be shown as NASDAQ: RIGL. The current share price for Rigel Pharmaceuticals is $0.83 (NASDAQ: RIGL) (as of Dec 2, 2022). (NYSE MKT: RIGL) There are now 172,836,336 shares of Rigel Pharmaceuticals outstanding. The market capitalization of Rigel Pharmaceuticals is $144.15M, with the stock now selling at $0.83 per share. On November 29, 2000, RIGL stock went public at a price of $63.99. Your return over the past 22 years if you had purchased RIGL stock at $63.99 would have been -98.7%, for just an annualized return of -17.9%. Competitors Of RIGL Verastem (VSTM), Spectrum Pharmaceuticals (SPPI), Merrimack Pharmaceuticals (MACK), Fortress Biotech (FBIO), Bolt Biotherapeutics (BOLT), Infinity Pharmaceuticals (INFI), Clovis Oncology (CLVS), Molecular Templates (MTEM), XOMA (XOMA), and Lexicon Pharmaceuticals are some of Rigel Pharmaceuticals' primary rivals (LXRX). Each of these businesses belongs to the "biotechnology" sector. Analysts favor other medical firms more than Rigel Pharmaceuticals. While the typical consensus recommendation for medical firms is Buy, Rigel Pharmaceuticals' rating is Hold. Verastem And Rigel Pharmaceuticals Verastem is outperformed by Rigel Pharmaceuticals in terms of earnings and revenue. Rigel Pharmaceuticals is currently the more cost-effective of the two stocks as it is selling at a cheaper cost ratio than Verastem.

With a beta of 0.63, Verastem's share price is predicted to be 37% less volatile than that of the S&P 500. When compared to the S&P 500, Rigel Pharmaceuticals does have a beta of 1.25, indicating that its RIGL stock price is 25% more volatile. When compared by MarketBeat users, Verastem received 150 more exceed votes than Rigel Pharmaceuticals. However, just 67.24% of individuals chose to vote for Verastem to outperform, compared to 69.61% who chose Rigel Pharmaceuticals. Institutional investors hold 58.6% of the shares of Verastem. Institutional investors now hold 80.9% of the shares of Rigel Pharmaceuticals. Insiders are the owners of 2.9% of the Verastem stock. Insiders own 6.4% of the shares of Rigel Pharmaceuticals, in contrast. A company's solid organizational ownership is a sign that hedge funds, big money managers, and endowments think it's prepared for long-term success. With a current consensus price objective of $5.00, Verastem might rise by 1,041.03%. With a $3.96 consensus price objective, Rigel Pharmaceuticals may rise by 374.91% from current levels. Analysts clearly perceive Verastem as being more favorable as Rigel Pharmaceuticals, given its higher consensus rating and more potential upside. What Date Will Rigel Pharmaceuticals Report Earnings? However, based on the report dates from the previous year, Rigel Pharmaceuticals estimates that its next earnings day will be on Tuesday, March 7, 2023. Rigel Pharmaceuticals (NASDAQ:RIGL) topped the analysts' consensus expectation of ($0.13) by $0.02 with its ($0.11) earnings per share (EPS) for the prior quarter. The reported yearly revenue for Rigel Pharmaceuticals (NASDAQ:RIGL) is $149.24 million. The reported net income for Rigel Pharmaceuticals (NASDAQ:RIGL) is -$17.91 million. Over the previous four quarters, RIGL's earnings per share were negative $0.48. Most Recent Analyst Recommendations From RIGL On December 2, 2022, Yigal Nochomovitz, a Citigroup bottom 6% analyst, increases RIGL to a solid investment rating. On November 4, 2022, Gary Nachman, a bottom 13% economist with BMO Capital, lowers their price objective for RIGL from $4 to $3 while maintaining a Buy recommendation. On August 18, 2022, Joseph Pantginis, rated bottom 10% analyst with HC Wainwright & Co., keeps RIGL with the a buy rating and increases their price objective from $7.00 to $15.00. On August 17, 2022, Do Kim, a high 33% analysts from Piper Sandler, retains RIGL with a hold recommendation and increases their price objective for the RIGL stock from $1.00 to $2.00. Financial Summary For RIGL Financial due diligence studies that RIGL passed show that it has a 70748000 cash burn. It has at least a year's worth of coverage in the form of cash and short-term investments. On the RIGL cash balance, short-term assets outnumber long-term liabilities. On the RIGL accounting records, short-term assets exceed short-term liabilities. Financial Due Diligence Tests that Fail: In the previous year, RIGL's profit margin decreased from -9.9% to -92.4%. The RIGL ratio of debt to equity is negative at -6.83. The total debt of RIGL is still negative. RIGL has $81.64M in short-term investments and cash. This is insufficient to fund its $70.75M yearly cash burn. Asset To Liability Ratio There are more short-term assets ($110.44M) than short-term liabilities ($47.27M) for RIGL. Long-term liabilities ($88.18M) are less than short-term assets ($110.44M) for RIGL. Since RIGL's debt to shareholder equity ratio (-6.83) is still negative, we do not take into account whether debt has decreased over the last five years. It is more concerning than a high ratio when RIGL's proportion of debt to equity (-6.83) is negative. Cash burn for the upcoming year ($70.75M) exceeds RIGL's cash & short-term investments ($81.64M). The profit margin for RIGL dropped by (-82.5%) in the previous year, going from (-9.9%) to (-92.4%). For at least a year, RIGL's cash & short-term investment ($81.64M) can fund its cash burn ($70.75M).

When factoring in a healthy margin of safety, RIGL ($0.83) is not considerably low (2.67%) in comparison to our estimate of its market valuation price of $0.86 based on the discounted cash flow (DCF) modeling. Scoring For RIGL Value: RIGL has a Value score of 14, which is higher than the industry average for Biotechnology. Right now, only one of RIGL's seven due diligence checks is passing. Finances: RIGL has a Financials score of 11, which is higher than the industry average for the Biotechnology sector. Only one of RIGL's seven due diligence checks is being passed. Forecast: The RIGL forecast score is 0, that is the same as the mean for the biotechnology sector. RIGL is failing 0 of 9 checks for due diligence. Performance: RIGL has a performance score of 43, which is higher than the average for the biotechnology sector. 3 from out 10 due diligence processes are being passed by RIGL. Dividend: Considering Rigel Pharmaceuticals hasn't recently paid dividends, we don't assign a score to this factor. How To Purchase Rigel Pharmaceuticals Stock Here are the six steps once more for purchasing Rigel Pharmaceuticals shares. Find out where to purchase shares in Rigel Pharmaceuticals. Open an account with a brokerage. Add your information after selecting your preferred payment method. Your brokerage account with the money. Analyze the shares of Rigel Pharmaceuticals. Purchase your RIGL product. Select whether you want to acquire RIGL stock at the spot price or at a preset price using a limit order. Get up-to-date information regarding your RIGL stock position. Make a watchlist of important changes regarding your new RIGL stock purchase.   RIGL Stock Forecast 2022 Six Wall Street analysts who follow NASDAQ: RIGL agree that the RIGL stock is a buy. Out of 6 analysts, 0 (%) suggest RIGL as a Sell, 0 (%) recommend RIGL as a Strong Sell, 1 (16.67%) recommends RIGL as a Strong Buy, 2 (33.33%) as a Buy, 3 (50%) as a Hold, and 0 (%) as a Hold Strong Sell. The revenue for Rigel Pharmaceuticals in 2022 is -$82,615,000. The average estimate of RIGL's 2022 profits from 5 Wall Street analysts is -$89,874,895, with the correct figure coming in at -$98,516,712 and the highest estimate coming in at -$81,233,078. RIGL Stock Forecast 2023 With the lowest RIGL earnings projection at -$82,961,441 and the highest RIGL statements forecast at -$36,295,631. 5 Wall Street analysts expect RIGL will earn -$57,035,991 in 2023. RIGL's revenue is expected to be $19,895,363,473 on average by 4 Wall Street analysts in 2023. The lowest RIGL revenue projection is $16,509,326,815, as well as the highest is $25,209,216,624. Analysts predict that RIGL's EPS will just be -$0.33 on average for 2023, with the lowest estimate being -$0.48 and the highest estimate being -$0.21. RIGL Stock Forecast 2024 With the lowest revenue RIGL stock forecast at $18,104,606,196 and the largest income RIGL stock forecast at $31,308,438,085, RIGL is expected to create $23,493,815,989 in sales in 2024. The estimated EPS for RIGL in 2024 will be -$0.17 (minimum: -$0.26, maximum: -$0.10). (NASDAQ: RIGL) is expected to have a ROA of -11.96%, which is worse than the predicted 13.22% average for the US Biotechnology industry. (NASDAQ: RIGL) is expected to have a dismal ROE of N/A. In the last 12 months, RIGL has not distributed any dividends. RIGL Stock Forecast 2025 12 forecasts are made for each month of 2025 for the price of Rigel Pharmaceuticals stock, with an average price prediction of $1.68, a high prognosis of $1.81, and a low prediction of $1.38. The typical Rigel Pharmaceuticals stock estimate for 2025 shows a decline from the most recent price of $2.45000004768372 of -31.53%. RIGL Stock Forecast 2027 12 RIGL stock forecast are made for each monthly of 2027 for the RIGL stock forecast for 2027 (five years), with an average prediction of $1.17, a high prognosis of $1.27, and a low prediction of $1.11. The median RIGL stock forecast for 2027 demonstrates a decrease from the most latest market o

f $2.45000004768372 of -52.27%. RIGL Stock Forecast 2030 Twelve RIGL stock forecast are made to every month of 2030 regarding the RIGL stock forecast, with an average RIGL stock forecast of $1.02, a high prognosis of $1.08, and just a low RIGL stock forecast of $0.98. From the most latest price of $2.45000004768372 to the consensus Rigel Pharmaceuticals stock forecast 2030, a -58.49% decline has occurred. RIGL Stock Forecast 2032 Four RIGL stock forecast are made for each month of 2032 for the RIGL stock forecast for 2032 (10 years), with an average prediction of $0.93, a high prediction of $0.93, and a low prediction of $0.92. The typical RIGL stock forecast for 2032 shows a decline from the most recent price of $2.45000004768372 of -62.21%.